Ionis Pharmaceuticals, Inc. ranks below the peer group median, with growth as the main structural strength, while profitability is less supportive than the other dimensions. The market setup has weakened, with clear trend damage and relative performance under pressure.
Peer-relative scores, weakest to strongest
Ionis Pharmaceuticals develops RNA-targeted therapies for a range of diseases, focusing on innovative treatments. The company’s business model centers on advancing clinical milestones in the RNA therapeutics field.
Ionis’s valuation depends on anticipated future developments rather than current operational results. An 87% year-over-year revenue growth indicates commercial momentum, but with an operating margin of -47.7%, the business is not yet profitable. Consequently, every pipeline setback causes significant share price reactions because the market prices in expected clinical progress rather than current earnings. As an RNA therapy specialist, Ionis’s performance is closely linked to clinical milestones and regulatory outcomes, so the market prices in each new data point or pipeline update with heightened sensitivity, often leading to amplified share price swings with every perceived advance or setback. In this case, anticipated developments have a greater impact than current financial metrics—each setback has a pronounced effect on valuation. Here, story trumps balance sheet — every failure costs double.
Break down IONS's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.